Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Volume 21, Issue 3
  5. Article
Volume 21, Issue 3
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Background

Metabolic syndrome comprises various conditions like abdominal obesity, insulin resistance, elevated triglyceride levels, reduced HDL, and high blood pressure, which pose significant health challenges globally. It's imperative to determine its prevalence in specific populations to formulate effective preventive measures.

Objective

This systematic review and meta-analysis aimed to determine the prevalence of metabolic syndrome in the Qatari population.

Methods

Using the PRISMA guidelines, a systematic search was executed on PubMed until July 2023 with keywords “Metabolic syndrome” and “Qatar.” Eligibility criteria included human subjects, studies assessing metabolic syndrome components, and research conducted in Qatar or on Qatari subjects. The quality of the studies was evaluated using the Newcastle-Ottawa Scale (NOS). Pooled prevalence rates were calculated using the inverse variance weighting meta-analysis.

Results

Out of 237 studies, 14 met our inclusion criteria, with a combined sample size of 14,772 from the Qatari population. The overall pooled prevalence of metabolic syndrome was 26%. The ATP III and IDF criteria exhibited significant differences in prevalence rates, with the IDF criteria showing a higher prevalence. Patients in the age of 40 or older demonstrated a higher prevalence compared to the younger group. Studies post-2018 reported a decreasing trend in metabolic syndrome prevalence.

Conclusion

The prevalence of metabolic syndrome in the Qatari population is comparable to rates in the Middle East. The study underscores the need for tailored interventions and strategies, especially targeting the older age group. Continuous research and monitoring are essential to track and understand the disease's progression in Qatar.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998286706240129074153
2024-02-28
2024-11-26

  • From This Site

    /content/journals/cdr/10.2174/0115733998286706240129074153
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LiW. QiuX. MaH. GengQ. Incidence and long-term specific mortality trends of metabolic syndrome in the United States.Front. Endocrinol.2022131029736
     [Google Scholar]
  2. LimS.S. VosT. FlaxmanA.D. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010.Lancet201238098592224226010.1016/S0140‑6736(12)61766‑8 23245609
     [Google Scholar]
  3. GiganteA. IannazzoF. NavariniL. Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis.Clin. Rheumatol.202140104253425810.1007/s10067‑021‑05731‑6 33839992
     [Google Scholar]
  4. ZhuL. SpenceC. YangW.J. MaG.X. The IDF definition is better suited for screening metabolic syndrome and estimating risks of diabetes in asian american adults: Evidence from NHANES 2011–2016.J. Clin. Med.2020912387110.3390/jcm9123871 33260754
     [Google Scholar]
  5. GrundyS.M. CleemanJ.I. DanielsS.R. Diagnosis and management of the metabolic syndrome.Circulation2005112172735275210.1161/CIRCULATIONAHA.105.169404 16157765
     [Google Scholar]
  6. AlbertiK.G.M.M. ZimmetP. ShawJ. Metabolic syndrome-a new world‐wide definition. A Consensus Statement from the International Diabetes Federation.Diabet. Med.200623546948010.1111/j.1464‑5491.2006.01858.x 16681555
     [Google Scholar]
  7. AlbertiK.G.M.M. EckelR.H. GrundyS.M. Harmonizing the metabolic syndrome.Circulation2009120161640164510.1161/CIRCULATIONAHA.109.192644 19805654
     [Google Scholar]
  8. OuzzaniM. HammadyH. FedorowiczZ. ElmagarmidA. Rayyan—a web and mobile app for systematic reviews.Syst. Rev.20165121010.1186/s13643‑016‑0384‑4 27919275
     [Google Scholar]
  9. HoueissP. NjeimR. TamimH. Urinary 20-HETE: A prospective Non-Invasive prognostic and diagnostic marker for diabetic kidney disease.J. Adv. Res.20234410911710.1016/j.jare.2022.04.013 36725183
     [Google Scholar]
  10. Al ShammaaA. Al-ThaniA. Al-KaabiM. Al-SaeedK. AlanaziM. ShiZ. Serum magnesium is inversely associated with body composition and metabolic syndrome.Diabetes Metab. Syndr. Obes.2023169510410.2147/DMSO.S391369 36760601
     [Google Scholar]
  11. AlsuwaidiH.N. AhmedA.I. AlkorbiH.A. Association between metabolic syndrome and decline in cognitive function: A cross-sectional study.Diabetes Metab. Syndr. Obes.20231684985910.2147/DMSO.S393282 36974329
     [Google Scholar]
  12. IbrahimT. AhmedA.F. NofalM. HegazyA. GhomrawiH.M.K. Metabolic syndrome and the likelihood of knee pain and functional disability: Evidence from a large middle eastern population-based study.BMC Musculoskelet. Disord.202324163410.1186/s12891‑023‑06685‑3 37542219
     [Google Scholar]
  13. RizkN. AminM. YousefM. Yousef. A pilot study on metabolic syndrome and its associated features among Qatari schoolchildren.Int. J. Gen. Med.2011452152510.2147/IJGM.S21103 21845059
     [Google Scholar]
  14. IsmailM.S. Metabolic syndrome among obese Qataris attending primary health care centers in Doha, 2010.J. Family Community Med.201219171110.4103/2230‑8229.94004 22518352
     [Google Scholar]
  15. BenerA. Al-HamaqA.O.A.A. DafeeahE.E. A two fold risk of metabolic syndrome in a sample of patients with schizophrenia: Do consanguinity and family history increase risk?Diabetes Metab. Syndr.201481242910.1016/j.dsx.2013.10.003 24661754
     [Google Scholar]
  16. BenerA. YousafzaiM.T. DarwishS. Al-HamaqA.O.A.A. NasrallaE.A. Abdul-GhaniM. Obesity index that better predict metabolic syndrome: Body mass index, waist circumference, waist hip ratio, or waist height ratio.J. Obes.20132013269038
     [Google Scholar]
  17. Al ThaniM. Al ThaniA. Al-ChetachiW. A ‘high risk’ lifestyle pattern is associated with metabolic syndrome among qatari women of reproductive age: A cross-sectional national study.Int. J. Mol. Sci.201617669810.3390/ijms17060698 27271596
     [Google Scholar]
  18. Al-ThaniM.H. Al-ThaniA.A.M. CheemaS. Prevalence and determinants of metabolic syndrome in Qatar: Results from a National Health Survey.BMJ Open201669e00951410.1136/bmjopen‑2015‑009514 27601485
     [Google Scholar]
  19. HammoudehS. GhuloumS. MahfoudZ. The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: A cross sectional comparative study.BMC Psychiatry20181818110.1186/s12888‑018‑1662‑6 29587717
     [Google Scholar]
  20. GanjiV. SukikA. AlaayeshH. RasoulinejadH. ShraimM. Serum vitamin D concentrations are inversely related to prevalence of metabolic syndrome in Qatari women.Biofactors202046118018610.1002/biof.1572 31512799
     [Google Scholar]
  21. HamedN. SolimanA. De SanctisV. The prevalence of the different components of the metabolic syndrome (Mets) in obese nondiabetic children and young adolescents and their anthropometric data in relation to parents.Acta Biomed.2021924e2021321 34487087
     [Google Scholar]
  22. MirF.A. MallR. IskandaraniA. Characteristic MicroRNAs linked to dysregulated metabolic pathways in Qatari adult subjects with obesity and metabolic syndrome.Front. Endocrinol.20221393708910.3389/fendo.2022.937089 35937842
     [Google Scholar]
  23. Al-DabhaniK. TsilidisK.K. MurphyN. Prevalence of vitamin D deficiency and association with metabolic syndrome in a Qatari population.Nutr. Diabetes201774e26310.1038/nutd.2017.14 28394362
     [Google Scholar]
  24. RochlaniY. PothineniN.V. KovelamudiS. MehtaJ.L. Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds.Ther. Adv. Cardiovasc. Dis.201711821510.1177/1753944717711379
     [Google Scholar]
  25. AnsarimoghaddamA. AdinehH.A. ZarebanI. IranpourS. HosseinZadeh A, Kh F. Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies.Diabetes Metab. Syndr.201812219520110.1016/j.dsx.2017.11.004 29203060
     [Google Scholar]
  26. GarveyW.T. RyanD.H. HenryR. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.Diabetes Care201437491292110.2337/dc13‑1518 24103901
     [Google Scholar]
  27. RegufeV.M.G. PintoC.M.C.B. PerezP.M.V.H.C. Metabolic syndrome in type 2 diabetic patients: A review of current evidence.Porto Biomed. J.202056e10110.1097/j.pbj.0000000000000101 33299950
     [Google Scholar]
  28. ShinS. JeeH. Prevalence of metabolic syndrome in the Gulf Cooperation Council countries: Meta-analysis of cross-sectional studies.J. Exerc. Rehabil.2020161273510.12965/jer.1938758.379 32161732
     [Google Scholar]
  29. ChackrewarthyS. GunasekeraD. PathmeswarenA. A comparison between revised NCEP ATP III and IDF definitions in diagnosing metabolic syndrome in an urban Sri Lankan population: The ragama health study.ISRN Endocrinol.201320131710.1155/2013/320176 23533799
     [Google Scholar]
  30. GundoganK. BayramF. GedikV. KayaA. KaramanA. DemirO. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults.Arch. Med. Sci.20139224310.5114/aoms.2013.34560
     [Google Scholar]
  31. SliemH.A. AhmedS. NemrN. El-SherifI. Metabolic syndrome in the middle east.Indian J. Endocrinol. Metab.20121616710.4103/2230‑8210.91193
     [Google Scholar]
  32. LeanM.E.J. Pathophysiology of obesity.Proc. Nutr. Soc.200059333133610.1017/S0029665100000379 10997648
     [Google Scholar]
  33. KassiE. PervanidouP. KaltsasG. ChrousosG. Metabolic syndrome: Definitions and controversies.BMC Med.2011914810.1186/1741‑7015‑9‑48 21542944
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998286706240129074153
Loading
Qatar's Silent Epidemic: A Comprehensive Meta-analysis on the Prevalence of Metabolic Syndrome
Curr. Diabetes Rev. 21, E280224227488 (2025); https://doi.org/10.2174/0115733998286706240129074153
/content/journals/cdr/10.2174/0115733998286706240129074153
/content/journals/cdr/10.2174/0115733998286706240129074153
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): ATP III; cardiovascular; IDF; lipoproteins; Metabolic syndrome; triglyceride

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test